Plexxikon

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Drug development, Molecular genetics, Research, FDA, Inflammation, Roche, Doctor of Philosophy, Heidelberg University, Therapy, Gastrointestinal cancer, Plexxikon, University, Max Planck Society, Wellington Partners, Growth, Patient

"We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.

Key Points: 
  • "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.
  • "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success.
  • I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board."
  • Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry.

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

Retrieved on: 
Friday, January 6, 2023
Yale University, CSO, Doctor of Philosophy, Research, Genentech, Brain, Science, Berkeley, Octant, Patient, Eye, University, Plexxikon, Chemistry, Marketing, Pharmaceutical industry

“The next few years are poised to be transformational for our company as we advance our extensive complement pipeline, with several mid-to-late-stage trials underway.

Key Points: 
  • “The next few years are poised to be transformational for our company as we advance our extensive complement pipeline, with several mid-to-late-stage trials underway.
  • It’s a pleasure to welcome Rick back to the Annexon team to lead our research efforts as CSO.
  • “Annexon has built an impressive pipeline of classical complement inhibitors for the body, brain and eye,” said Dr. Artis.
  • I am thrilled to partner with the team to continue building upon the pioneering research at Annexon to address complement-mediated diseases.”

Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, April 26, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Sorafenib, Protein, University of California, San Francisco, Medicine, Biotechnology, Coronavirus Scientific Advisory Board (Turkey), Plexxikon, Leadership, Department, Patient, Intrinsically disordered proteins, Medicinal chemistry, Onyx Pharmaceuticals, Professor, Biology, FDA, University, Therapy, Pharmaceutical industry, Fine chemical

Ambagon Therapeutics , a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • Ambagon Therapeutics , a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board.
  • Dr. Bollag brings extensive experience in structure-based drug discovery and the development of oncology therapeutics.
  • This is a perfect moment to welcome Gideon to the team, during a pivotal period of discovery and development at Ambagon and following a successful $85 million Series A launch in January, said Nancy Pryer, Chief Scientific Officer of Ambagon Therapeutics.
  • Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes.

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Retrieved on: 
Thursday, April 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Protein, Board, McGovern Institute for Brain Research, Howard Hughes Medical Institute, MIT, Berkeley, Genetics, Coronavirus Scientific Advisory Board (Turkey), Plexxikon, Genentech, Research, Genomics, Yale University, Psychiatry, Cognitive science, Elan, Doctor of Philosophy, Drug discovery, Stanford University, Lists of diseases, Patient, Harvard College, Series, Allen & Company, CSO, Genome, Harvard University, Informatics, Physics, Molecular Discovery, DMS, Bristol Myers Squibb, Biology, Eukaryote, Partnership, University, James, Senior, CRISPR, Partner (business rank), Therapy, Broad Institute, Biological engineering, Synthetic biology, Pharmaceutical industry, Fine chemical, Chemistry, Brain, Octant, Neuroscience

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Key Points: 
  • In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.
  • Octant also plans to develop multiple additional therapeutic programs in small molecule chaperone therapies for rare genetic diseases.
  • Immunogenetics and immunopharmacology are among the most complex areas in biology and drug discovery, with potential to impact countless patients, continued Kosuri.
  • As Chief Scientific Officer, Rick Artis will be responsible for Octant's chemistry function and drug discovery and development programs.

Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, December 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, PFS, HIV disease progression rates, Society, Immunoglobulin G, NSCLC, Technology, Lung cancer, Disease, Medicine, Patritumab, American Society of Clinical Oncology, Patient, Trastuzumab deruxtecan, ADC, HER3, Cardiovascular disease, Gefitinib, BTD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, DXD, Cell proliferation, Plexxikon, Large-cell lung carcinoma, Safety, Thought, Survival, ORR, TKI, RDE, Quality of life, Treatment of lung cancer, Incidence, EGFR, Progression-free survival, Cancer, Cohort, MD, R, Cleavage, Afatinib, Histology, Research, Laboratory, Sustainable development, ASCO, Food, Pharmacokinetics, Daiichi Sankyo, Lead, Lung, FDA, Pharmaceutical industry, Medical imaging, Platinum, Fine chemical, Limited, American Association for Cancer Research, Non-Small Cell Lung Cancer, HER3, the Phase 1 Non-Small Cell Lung Cancer Study, Patritumab Deruxtecan, Daiichi Sankyo in Oncology, NON-SMALL CELL LUNG CANCER, HER3, THE PHASE 1 NON-SMALL CELL LUNG CANCER STUDY, PATRITUMAB DERUXTECAN, DAIICHI SANKYO IN ONCOLOGY

The FDA granted the BTD based on data from the dose escalation portion and two expansion cohorts of a three-cohort phase 1 study of patritumab deruxtecan (cohorts 1 and 3a).

Key Points: 
  • The FDA granted the BTD based on data from the dose escalation portion and two expansion cohorts of a three-cohort phase 1 study of patritumab deruxtecan (cohorts 1 and 3a).
  • This is the first BTD for patritumab deruxtecan and the seventh BTD across Daiichi Sankyos oncology portfolio.
  • The Breakthrough Therapy Designation for patritumab deruxtecan acknowledges the need for new treatment approaches to overcome resistance and improve survival in patients with metastatic TKI-resistant, EGFR-mutated non-small cell lung cancer, said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • The global, multicenter, open label, two-part phase 1 study is evaluating patritumab deruxtecan in previously treated patients with metastatic or unresectable NSCLC.

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Prostate, Congress, Patient, Sustainable development, Lung cancer, Index (publishing), Immunoglobulin G, Safety, Head, Adult, Dehydration, Causality, Breast, Breast cancer, Chills, Bendell, Progression-free survival, Interstitial lung disease, Plexxikon, Research, Bachelor of Pharmacy, Oncology, Thought, Bladder cancer, DXD, CRO, Veni, vidi, vici, Fatigue, Endometrial cancer, ILD, MD, ADC, Anemia, Cancer, Squamous cell carcinoma, Lymphocyte, Laboratory, Vomiting, Appetite, European Society for Medical Oncology, Death, Cardiovascular disease, Senior, MTD, Sarah Cannon Research Institute, Melanoma, Quality of life, Technology, Oncotarget, Doctor of Philosophy, PRS, RDE, Cleavage, Nausea, Daiichi Sankyo, Diarrhea, Fever, Lung, Pharmaceutical industry, Medical imaging, Fine chemical, Silviculture, B7-H3, the DS-7300 Study, DS-7300, Daiichi Sankyo in Oncology, B7-H3, THE DS-7300 STUDY, DS-7300, DAIICHI SANKYO IN ONCOLOGY

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).

Plexxikon Wins Patent Infringement Case Against Novartis

Retrieved on: 
Friday, July 23, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Companies, Pharmaceutical companies, Life sciences, Daiichi Sankyo, Plexxikon, Patent, Novartis, Plexxikon, Daiichi Sankyo, PLEXXIKON, DAIICHI SANKYO

Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that it has won its patent infringement lawsuit against Novartis.

Key Points: 
  • Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that it has won its patent infringement lawsuit against Novartis.
  • The jury rejected Novartiss arguments, upheld the validity of Plexxikons patents, and found Novartiss infringement was willful.
  • Plexxikon was awarded damages of $178 million for past infringement of its patents and will receive additional royalty payments for future sales of Tafinlar in the United States through the life of the patents.
  • In the suit, Plexxikon alleged that Novartis owed the company substantial royalties on its drug Tafinlar, which infringes two Plexxikon patents (U.S. Patent Nos.

Plexxikon Announces Key Executive Appointments; Dr. Chao Zhang Named Chief Executive Officer and Marguerite Hutchinson, JD, Named Chief Operating Officer

Retrieved on: 
Thursday, July 1, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Companies, Daiichi Sankyo, Plexxikon, Pharmaceutical companies, Zhang, Plexxikon, Daiichi Sankyo, PLEXXIKON, DAIICHI SANKYO

Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that Chao Zhang, PhD, has been promoted to chief executive officer from chief scientific officer.

Key Points: 
  • Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that Chao Zhang, PhD, has been promoted to chief executive officer from chief scientific officer.
  • Dr Zhang will succeed Gideon Bollag, PhD, who will transition to a part-time position as chief biologist.
  • In addition, Marguerite Hutchinson, JD, has been promoted to chief operating officer and general counsel.
  • I am honored to take the helm of Plexxikon and thank Gideon for his leadership over the past eight years.

VectivBio Strengthens Business Development Capabilities with Key Appointments

Retrieved on: 
Wednesday, November 4, 2020
Daiichi Sankyo, Companies, Health care, Clinical medicine, Plexxikon, Vemurafenib, Pharmaceutical industry in China, PTC Therapeutics, Lonza Group

BASEL, Switzerland, Nov. 4, 2020 /PRNewswire/ -- VectivBio AG , a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D. , as Chief Business Officer and Aditya Venugopal, Ph.D. , as Vice President of Business Development.

Key Points: 
  • BASEL, Switzerland, Nov. 4, 2020 /PRNewswire/ -- VectivBio AG , a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D. , as Chief Business Officer and Aditya Venugopal, Ph.D. , as Vice President of Business Development.
  • Most recently, she served as Global Head of licensing at Lonza AG where she built the new licensing business unit, led research and development and drove the spin-off of Affinia Therapeutics.
  • She led many deals for Roche Partnering, including licensing ZELBORAF (vemurafenib) from Plexxikon and establishing a key CNS partnership with PTC Therapeutics.
  • Dr. Venugopal was most recently an Executive Director at Intercept Pharmaceuticals, where he held roles leading corporate strategic planning and business development (BD).

Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT

Retrieved on: 
Friday, June 26, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Organ systems, Rare diseases, Chemical compounds, Pigmented villonodular synovitis, Villonodular synovitis, Pexidartinib, Plexxikon, Colony stimulating factor 1 receptor, Daiichi Sankyo, Macrophage colony-stimulating factor, Pexidartinib, TGCT (PVNS/GCT-TS), Daiichi Sankyo

Pexidartinib is an oral small molecule that inhibits CSF1R (colony stimulating factor-1 receptor), which is a primary growth driver of abnormal cells in the synovium that cause TGCT.

Key Points: 
  • Pexidartinib is an oral small molecule that inhibits CSF1R (colony stimulating factor-1 receptor), which is a primary growth driver of abnormal cells in the synovium that cause TGCT.
  • Pexidartinib was discovered by Plexxikon Inc., the small molecule structure-guided R&D center of Daiichi Sankyo.
  • TGCT, also referred to as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is a rare, typically non-malignant tumor that can be locally aggressive.
  • In these cases, the tumor may be difficult to remove and/or may not be amenable to improvement with surgery.